BeOne Medicines (ONC) Income from Non-Controlling Interests (2017 - 2020)

BeOne Medicines (ONC) posted quarterly Income from Non-Controlling Interests of $96000.0 for Q4 2020, down 42.17% year-over-year from $166000.0 in Q1 2020, and up 106.89% quarter-over-quarter from -$1.4 million in Q3 2020.

BeOne Medicines (ONC) Income from Non-Controlling Interests (2017 - 2020) Analysis & Trends

BeOne Medicines (ONC) has reported Income from Non-Controlling Interests for 4 consecutive years, with $96000.0 the latest figure, recorded in Q4 2020.

  • In Q4 2020, Income from Non-Controlling Interests fell 42.17% year-over-year to $96000.0; the TTM figure through Sep 2021 stood at $96000.0 (up 102.71% YoY), while the FY2020 annual figure was -$3.6 million, down 85.49% from the prior year.
  • Income from Non-Controlling Interests advanced to $96000.0 in Q4 2020 per ONC's latest filing, from -$1.4 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $1.5 million in Q4 2018 and bottomed at -$1.4 million in Q3 2020.
  • Historically, Income from Non-Controlling Interests has averaged -$401666.7 across 4 years, with a median of -$429000.0 in 2019.
  • On a YoY basis, Income from Non-Controlling Interests climbed as much as 3493.02% in 2018 and fell as far as 513.33% in 2018.
  • BeOne Medicines' Income from Non-Controlling Interests stood at $43000.0 in 2017, then soared by 3493.02% to $1.5 million in 2018, then tumbled by 89.26% to $166000.0 in 2019, then slumped by 42.17% to $96000.0 in 2020.
  • Business Quant data shows ONC's Income from Non-Controlling Interests at $96000.0 in Q4 2020, -$1.4 million in Q3 2020, and -$1.1 million in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 63.60 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -100.77 Mn

Historic Data

Download Data
DateValue
Dec 31, 2020 96,000.00
Sep 30, 2020 -1.39 Mn
Jun 30, 2020 -1.12 Mn
Mar 31, 2020 -1.20 Mn
Dec 31, 2019 166,000.00
Sep 30, 2019 -1.30 Mn
Jun 30, 2019 -384,000.00
Mar 31, 2019 -429,000.00
Dec 31, 2018 1.55 Mn
Sep 30, 2018 -461,000.00
Jun 30, 2018 -828,000.00
Mar 31, 2018 -520,000.00
Dec 31, 2017 43,000.00
Sep 30, 2017 -102,000.00
Jun 30, 2017 -135,000.00